Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LD02GIFRO for GI Motility Recovery in Colon Resection
NCT01624571Phase 2Completed
- Sponsor
- LG Chem
- Start
- Mar 2012
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LD02GIFRO in postoperative ileus (POI) (4 arms), sponsored by LG Chem. Primary endpoint: Improvement of gastrointestinal motility up to 14 days. Started Mar 2012; status: completed.
02
Drugs
LD02GIFRO
03
Conditions
postoperative ileus (POI)
Beyond the preview
Go deeper on NCT01624571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01624571.